- Question from ChessM: Are all bisphosphonates the same? Are there any clinical trials that are currently under way that are testing Zometa with postmenopausal breast cancer survivors?
- Answers - Generosa Grana, M.D., F.A.C.P All bisphosphonates are not the same. They vary in their strength and their toxicity, and what role they each play in early-stage breast cancer is not yet well defined. The oral bisphosphonates -- clodronate (which is FDA approved in Europe for osteoporosis), Actonel (chemical name: risedronate), Fosamax (chemical name: alendronate sodium), and Boniva (chemical name: ibandronate), which are all approved by the FDA in the U.S., are all oral bisphosphonates of varying activity. They are less intensive than Zometa. There are several trials going, both in the United States and Europe, looking at all of these bisphosphonates in postmenopausal women with breast cancer. Again, we eagerly await the results of those trials to see if these agents have varying levels of anti-cancer activity as well as varying levels of toxicity.
The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.
Editor's Note: This conference took place in June 2008.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.